Amgen Inc.
BINDING MOLECULES FOR BCMA AND CD3
Last updated:
Abstract:
The present invention relates to a binding molecule which is at least bispecific comprising a first and a second binding domain, wherein the first binding domain is capable of binding to epitope cluster 3 of BCMA, and the second binding domain is capable of binding to the T cell CD3 receptor complex. Moreover, the invention provides a nucleic acid sequence encoding the binding molecule, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention provides a process for the production of the binding molecule of the invention, a medical use of said binding molecule and a kit comprising said binding molecule.
Status:
Application
Type:
Utility
Filling date:
15 Feb 2022
Issue date:
11 Aug 2022